5 recruiting, 1 withdrawn. 2 Phase 2, 2 Phase 3, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
| Phase 3 | 2 | Recruiting 2 |
| Not applicable | 1 | Withdrawn 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow MF: new trials by email Literature Review of MF trials Research Report on MF
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Intermediate to High Risk Myelofibrosis Flonoltinib Maleate - MF | Phase 2 | Recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 64 | 2026-03-18 | 2026-08-13 |
| A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis Flonoltinib 75mg, Ruxolitinib Phosphate - MF | Phase 3 | Recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 105 | 2026-02-13 | 2026-08-13 |
| MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) Polycythemia Vera, ET (Essential Thrombocythemia) | Recruiting | MPN Research Foundation | 5000 | 2025-09-26 | 2026-01-23 | |
| Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib Navtemadlin, Navtemadlin placebo, Ruxolitinib - Myelofibrosis, Post-PV MF | Phase 3 | Recruiting | Kartos Therapeutics, Inc. | 600 | 2024-06-03 | 2025-09-25 |
| A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors JAB-8263 - NSCLC, SCLC | Phase 1 / Phase 2 | Recruiting | Jacobio Pharmaceuticals Co., Ltd. | 152 | 2021-05-07 | 2026-01-09 |
| Ruxolitinib in Combination With Autotransplant RUXOLITINIB / INC 424, Filgrastim, Busulfan - Myelofibrosis, MF | Not applicable | Withdrawn | Marina Kremyanskaya | 2015-05-01 | 2016-08-12 |
Primary Myelofibrosis (3) · Blast Crisis (1) · Bone Marrow Neoplasms (1) · Disease Progression (1) · Hematologic Neoplasms (1) · Myeloproliferative Disorders (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Polycythemia Vera (1) · Rare Diseases (1) · Thrombocythemia, Essential (1)
Bone Marrow Diseases (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Myeloproliferative Disorders (2) · Neoplasms by Site (2) · Adnexal Diseases (1) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Carcinogenesis (1) · Cell Transformation, Neoplastic (1) · Chronic Disease (1) · Disease Attributes (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1)
ruxolitinib (3) · Busulfan (1) · Filgrastim (1) · navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid (1)
Chengdu Zenitar Biomedical Technology Co., Ltd (2) · Jacobio Pharmaceuticals Co., Ltd. (1) · Kartos Therapeutics, Inc. (1) · MPN Research Foundation (1) · Marina Kremyanskaya (1)
China (3) · United States (2) · Australia (1) · Austria (1) · Belgium (1) · Croatia (1) · Czechia (1) · France (1) · Georgia (1) · Germany (1) · Greece (1) · Hungary (1) · Italy (1) · Poland (1) · Portugal (1)
Marina Kremyanskaya, MD, PhD (1) · Miao Jia, Doctor (1) · Niu Ting (1) · Niu Ting, Doctor (1) · Raajit Rampal, MD, PhD (1) · Xiao Zhijian (1) · Xiao Zhijian, Doctor (1)